---
document_datetime: 2025-12-02 05:31:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/vydura.html
document_name: vydura.html
version: success
processing_time: 0.1105429
conversion_datetime: 2025-12-29 20:49:29.600721
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Vydura

[RSS](/en/individual-human-medicine.xml/67560)

##### Authorised

This medicine is authorised for use in the European Union

rimegepant Medicine Human Authorised

On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Vydura](#news-on)
- [More information on Vydura](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Vydura is a medicine used to treat migraine with or without aura (unusual visual or other sensory experiences) in adults. It is also used to prevent migraine in adults who have at least 4 migraines attacks a month.

Vydura contains the active substance rimegepant.

Expand section

Collapse section

## How is Vydura used?

Vydura is available as a freeze-dried wafer to be placed on or under the tongue, where it will dissolve.

Vydura is taken once a day for the treatment of migraine, and once every other day for prevention of migraine.

The medicine can only be obtained with a prescription.

For more information about using Vydura, see the package leaflet or contact your doctor or pharmacist.

## How does Vydura work?

A chemical messenger called calcitonin gene-related peptide (CGRP) contributes to the development of migraine. The active substance in Vydura, rimegepant, attaches to the receptor (target) for CGRP. By attaching to this receptor, the medicine prevents CGRP from binding to it. This helps treat migraine and also prevents migraines from occurring.

## What benefits of Vydura have been shown in studies?

Vydura was shown to be more effective than placebo (a dummy treatment) at treating migraine in three main studies involving a total of around 3,500 adults. Patients with a migraine attack causing moderate to severe headache recorded the level of pain two hours after treatment using a 4-point Likert scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain).

On average across the three studies, 20% of patients taking Vydura were headache pain-free after two hours, compared with 12% on average for those taking placebo. Vydura was also effective at treating other migraine symptoms such as photophobia (abnormal sensitivity of the eyes to light), phonophobia (abnormal sensitivity to sounds) or nausea (feeling sick): on average, around 36% of patients taking Vydura were free from one of the above symptoms two hours after treatment, compared with around 27% of those taking placebo.

Another study showed that Vydura is effective at reducing the number of days patients suffer from migraines. The study involved 747 adults who had between 4 to 18 migraine attacks a month; patients took Vydura or placebo every other day for up to 12 weeks. Those treated with Vydura had on average 4.3 fewer days with migraines during the last 4 weeks of the study, compared with 3.5 fewer days for patients on placebo.

## What are the risks associated with Vydura?

The most common side effect with Vydura (which may affect up to 1 in 10 people) is nausea. Hypersensitivity (allergic reaction) including dyspnoea (difficulty breathing) and severe rash may affect up to 1 in 100 people.

For the full list of side effects and restrictions of Vydura, see the package leaflet.

## Why is Vydura authorised in the EU?

Vydura was shown to be more effective than placebo at reducing headaches and other migraine symptoms and at reducing the number of days patients experienced migraine, although the size of the effect is considered modest. The safety profile of Vydura is considered favourable.

The European Medicines Agency therefore decided that Vydura's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Vydura?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Vydura have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Vydura are continuously monitored. Suspected side effects reported with Vydura are carefully evaluated and any necessary action taken to protect patients.

## Other information about Vydura

Vydura received a marketing authorisation valid throughout the EU on 25 April 2022.

Vydura : EPAR - Medicine Overview

Reference Number: EMA/231460/2022

English (EN) (119.23 KB - PDF)

**First published:** 11/05/2022

[View](/en/documents/overview/vydura-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-881)

български (BG) (142.85 KB - PDF)

**First published:**

11/05/2022

[View](/bg/documents/overview/vydura-epar-medicine-overview_bg.pdf)

español (ES) (118.77 KB - PDF)

**First published:**

11/05/2022

[View](/es/documents/overview/vydura-epar-medicine-overview_es.pdf)

čeština (CS) (140.93 KB - PDF)

**First published:**

11/05/2022

[View](/cs/documents/overview/vydura-epar-medicine-overview_cs.pdf)

dansk (DA) (117.33 KB - PDF)

**First published:**

11/05/2022

[View](/da/documents/overview/vydura-epar-medicine-overview_da.pdf)

Deutsch (DE) (120.95 KB - PDF)

**First published:**

11/05/2022

[View](/de/documents/overview/vydura-epar-medicine-overview_de.pdf)

eesti keel (ET) (107.23 KB - PDF)

**First published:**

11/05/2022

[View](/et/documents/overview/vydura-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.37 KB - PDF)

**First published:**

11/05/2022

[View](/el/documents/overview/vydura-epar-medicine-overview_el.pdf)

français (FR) (119.71 KB - PDF)

**First published:**

11/05/2022

[View](/fr/documents/overview/vydura-epar-medicine-overview_fr.pdf)

hrvatski (HR) (141 KB - PDF)

**First published:**

11/05/2022

[View](/hr/documents/overview/vydura-epar-medicine-overview_hr.pdf)

italiano (IT) (117.4 KB - PDF)

**First published:**

11/05/2022

[View](/it/documents/overview/vydura-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (149.35 KB - PDF)

**First published:**

11/05/2022

[View](/lv/documents/overview/vydura-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (141.03 KB - PDF)

**First published:**

11/05/2022

[View](/lt/documents/overview/vydura-epar-medicine-overview_lt.pdf)

magyar (HU) (138.05 KB - PDF)

**First published:**

11/05/2022

[View](/hu/documents/overview/vydura-epar-medicine-overview_hu.pdf)

Malti (MT) (142.92 KB - PDF)

**First published:**

11/05/2022

[View](/mt/documents/overview/vydura-epar-medicine-overview_mt.pdf)

Nederlands (NL) (118.1 KB - PDF)

**First published:**

11/05/2022

[View](/nl/documents/overview/vydura-epar-medicine-overview_nl.pdf)

polski (PL) (142.02 KB - PDF)

**First published:**

11/05/2022

[View](/pl/documents/overview/vydura-epar-medicine-overview_pl.pdf)

português (PT) (119.46 KB - PDF)

**First published:**

11/05/2022

[View](/pt/documents/overview/vydura-epar-medicine-overview_pt.pdf)

română (RO) (139.26 KB - PDF)

**First published:**

11/05/2022

[View](/ro/documents/overview/vydura-epar-medicine-overview_ro.pdf)

slovenčina (SK) (139.7 KB - PDF)

**First published:**

11/05/2022

[View](/sk/documents/overview/vydura-epar-medicine-overview_sk.pdf)

slovenščina (SL) (138.61 KB - PDF)

**First published:**

11/05/2022

[View](/sl/documents/overview/vydura-epar-medicine-overview_sl.pdf)

Suomi (FI) (116.41 KB - PDF)

**First published:**

11/05/2022

[View](/fi/documents/overview/vydura-epar-medicine-overview_fi.pdf)

svenska (SV) (117.18 KB - PDF)

**First published:**

11/05/2022

[View](/sv/documents/overview/vydura-epar-medicine-overview_sv.pdf)

Vydura : EPAR - Risk management plan summary

English (EN) (65.81 KB - PDF)

**First published:** 11/05/2022

[View](/en/documents/rmp-summary/vydura-epar-risk-management-plan-summary_en.pdf)

## Product information

Vydura : EPAR - Product Information

English (EN) (483.54 KB - PDF)

**First published:** 11/05/2022

**Last updated:** 14/04/2025

[View](/en/documents/product-information/vydura-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-454)

български (BG) (397.91 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/bg/documents/product-information/vydura-epar-product-information_bg.pdf)

español (ES) (351.4 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/es/documents/product-information/vydura-epar-product-information_es.pdf)

čeština (CS) (377.54 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/cs/documents/product-information/vydura-epar-product-information_cs.pdf)

dansk (DA) (360.44 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/da/documents/product-information/vydura-epar-product-information_da.pdf)

Deutsch (DE) (377.53 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/de/documents/product-information/vydura-epar-product-information_de.pdf)

eesti keel (ET) (339.03 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/et/documents/product-information/vydura-epar-product-information_et.pdf)

ελληνικά (EL) (367.08 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/el/documents/product-information/vydura-epar-product-information_el.pdf)

français (FR) (357.29 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/fr/documents/product-information/vydura-epar-product-information_fr.pdf)

hrvatski (HR) (360.49 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/hr/documents/product-information/vydura-epar-product-information_hr.pdf)

íslenska (IS) (359.78 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/is/documents/product-information/vydura-epar-product-information_is.pdf)

italiano (IT) (346.29 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/it/documents/product-information/vydura-epar-product-information_it.pdf)

latviešu valoda (LV) (363.18 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/lv/documents/product-information/vydura-epar-product-information_lv.pdf)

lietuvių kalba (LT) (346.35 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/lt/documents/product-information/vydura-epar-product-information_lt.pdf)

magyar (HU) (365.32 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/hu/documents/product-information/vydura-epar-product-information_hu.pdf)

Malti (MT) (387.9 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/mt/documents/product-information/vydura-epar-product-information_mt.pdf)

Nederlands (NL) (426.14 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/nl/documents/product-information/vydura-epar-product-information_nl.pdf)

norsk (NO) (352.59 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/no/documents/product-information/vydura-epar-product-information_no.pdf)

polski (PL) (378.62 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/pl/documents/product-information/vydura-epar-product-information_pl.pdf)

português (PT) (366.35 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/pt/documents/product-information/vydura-epar-product-information_pt.pdf)

română (RO) (358.27 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/ro/documents/product-information/vydura-epar-product-information_ro.pdf)

slovenčina (SK) (368.48 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/sk/documents/product-information/vydura-epar-product-information_sk.pdf)

slovenščina (SL) (363.83 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/sl/documents/product-information/vydura-epar-product-information_sl.pdf)

Suomi (FI) (337.88 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/fi/documents/product-information/vydura-epar-product-information_fi.pdf)

svenska (SV) (337.92 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

14/04/2025

[View](/sv/documents/product-information/vydura-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000254589 11/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Vydura : EPAR - All authorised presentations

English (EN) (24.43 KB - PDF)

**First published:** 11/05/2022

**Last updated:** 03/10/2022

[View](/en/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-829)

български (BG) (26.98 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/bg/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_bg.pdf)

español (ES) (24.57 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/es/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_es.pdf)

čeština (CS) (25.92 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/cs/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (25.64 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/da/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (25.77 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/de/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (24.88 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/et/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (27.36 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/el/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_el.pdf)

français (FR) (25.01 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/fr/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (24.81 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/hr/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (25.48 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/is/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_is.pdf)

italiano (IT) (24.66 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/it/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (25.58 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/lv/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (26.07 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/lt/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (26.62 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/hu/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (25.12 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/mt/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (24.66 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/nl/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (25.55 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/no/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_no.pdf)

polski (PL) (25.71 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/pl/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_pl.pdf)

português (PT) (25.07 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/pt/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_pt.pdf)

română (RO) (24.63 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/ro/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (26.2 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/sk/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (25.43 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/sl/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (24.98 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/fi/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (25.07 KB - PDF)

**First published:**

11/05/2022

**Last updated:**

03/10/2022

[View](/sv/documents/all-authorised-presentations/vydura-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Vydura Active substance rimegepant International non-proprietary name (INN) or common name rimegepant Therapeutic area (MeSH) Migraine Disorders Anatomical therapeutic chemical (ATC) code N02CD06

### Pharmacotherapeutic group

Antimigraine preparations, calcitonin gene-related peptide (CGRP) antagonists

### Therapeutic indication

Vydura is indicated for the

- Acute treatment of migraine with or without aura in adults;
- Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

## Authorisation details

EMA product number EMEA/H/C/005725

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Pfizer Europe MA EEIG

Boulevard de la Plaine 17

Opinion adopted 24/02/2022 Marketing authorisation issued 25/04/2022 Revision 7

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Vydura : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (144.43 KB - PDF)

**First published:** 14/04/2025

[View](/en/documents/procedural-steps-after/vydura-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Vydura : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (127.84 KB - PDF)

**First published:** 07/06/2022

**Last updated:** 24/01/2024

[View](/en/documents/procedural-steps-after/vydura-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Vydura : EPAR - Public Assessment Report

Adopted

Reference Number: EMA/CHMP/172260/2022

English (EN) (4.57 MB - PDF)

**First published:** 11/05/2022

[View](/en/documents/assessment-report/vydura-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Vydura

Adopted

Reference Number: EMA/CHMP/106030/2022

English (EN) (136.61 KB - PDF)

**First published:** 25/02/2022

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-vydura_en.pdf)

#### News on Vydura

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 February 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-21-24-february-2022) 25/02/2022

#### More information on Vydura

- [EMEA-002812-PIP02-20-M03 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002812-pip02-20-m03)
- [Post-authorisation Safety Study of Rimegepant in Patients with Migraine and History of Cardiovascular Disease in European Countries - post-authorisation study](https://catalogues.ema.europa.eu/study/104168)
- [Retrospective Cohort Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy - post-authorisation study](https://catalogues.ema.europa.eu/study/45953)

**This page was last updated on** 14/04/2025

## Share this page

[Back to top](#main-content)